Search

Displaying results 971 - 980 of 8515 in total
  1. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in

  2. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates). … Also known as _Albuminex_ 5% or 25%, one brand of human serum albumin is prepared from the pooled plasma of US donors in FDA-licensed facilities in the US [F229].

  3. Drug

    Thiotepa

    go.drugbank.com/drugs/DB04572
    ApprovedInvestigational

    It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

  4. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  5. Drug

    AT-301

    go.drugbank.com/drugs/DB16507
    Investigational

    AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine

  6. Drug

    Pentetic acid

    go.drugbank.com/drugs/DB14007
    ApprovedInvestigational

    [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469] … [A32501] It is currently considered, in all the dosage forms, as a member of the list of approved inactive ingredients for drug products by the FDA.

  7. Drug

    Molindone

    go.drugbank.com/drugs/DB01618
    Approved

    Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. … It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors.

  8. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy

  9. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment

  10. Drug

    Thiosulfuric acid

    go.drugbank.com/drugs/DB09499
    ApprovedInvestigational

    [A252827] Sodium thiosulfate is rapidly degraded in the stomach; therefore, it is normally administered through other routes, such as intravenous or topical. … Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, including food preservative, water de-chlorinator and paper pulp bleaching